ACR Open Rheumatol. 2021. Epub ahead of print. doi: 10.1002/acr2.11380This post hoc analysis shows that pain reduction was similar between opioid users and nonusers with baricitinib 2 mg and 4 mg, but not adalimumab.Use of opioids to treat RA-related pain has increased, yet long-term use has been associated with reduced efficacy and safety concerns. In addition, the misuse of opioids has resulted in a public health crisis in the United States and highlights the need for safe, effective nonaddictive alternatives for pain management. As such, Pope, et al. assessed pain reduction with baricitinib in patients with RA who either used opioids or did not use opioids during three Phase 3 trials.